TrialAn Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
Trial details
- Registry ID
- NCT04988867
- Phase
- Phase 2, Phase 3
Drug research
Trofinetide
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromeNCT04988867 | ACAD | Phase 2, Phase 3 | Terminated | 2023-05-31Actual |
| Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeNCT04279314 | ACAD | Phase 3 | Completed | 2022-08-19Actual |
| Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)NCT04181723 | ACAD | Phase 3 | Completed | 2021-10-28Actual |
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
Trial details
- Registry ID
- NCT04279314
- Phase
- Phase 3
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
Trial details
- Registry ID
- NCT04181723
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |